Every 10-Q that Matinas BioPharma Holdings, Inc. (MTNB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MTNB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MTNB filings page.
Matinas BioPharma Holdings, Inc. reported a net loss of $1,326 thousand for the quarter and $3,247 thousand for the six months ended June 30, 2026, narrowing losses from 2025. Total assets were $3,412 thousand, including $761 thousand of cash and cash equivalents and stockholders’ equity of $1,800 thousand.
The company continues to incur operating losses and states that existing cash is not sufficient to fund operations for 12 months, concluding that substantial doubt exists about its ability to continue as a going concern. It used $3,437 thousand of cash in operating activities in the first half of 2026.
Matinas agreed to a Business Combination with GH Power Inc., under which current Matinas equityholders are expected to own about 9% of the combined Pubco, and to sell its Nanotechnologies subsidiary (owner of MAT2203) to Azurity for up to $21,500 thousand plus royalties. It also raised $575 thousand via Series D preferred stock and $2,323 thousand through a warrant inducement. Completion of the Business Combination and Stock Sale is subject to multiple conditions and is not assured.
Matinas BioPharma Holdings, Inc. reported a Q1 2026 net loss of $1.9M, similar to the prior year, with cash and cash equivalents of $2.4M and total assets of $5.9M. Stockholders’ equity fell to $3.0M, down from $6.3M a year earlier.
The company, a clinical-stage biopharma built around its lipid nanocrystal (LNC) delivery platform and lead asset MAT2203, cut research and development spending to zero in the quarter while general and administrative costs stayed around $1.9M. Management discloses substantial doubt about its ability to continue as a going concern.
Matinas is seeking to monetize MAT2203 through a license, sale or partnership and may use its At-The-Market Sales Agreement with BTIG, but capacity is capped by Form S-3 public float limits. The NYSE American has notified the company that it is below stockholders’ equity listing standards, and Matinas has submitted a compliance plan.
Matinas BioPharma Holdings (MTNB) reported Q3 2025 results. The company posted a Q3 net loss of $1.532 million and a nine‑month net loss of $8.433 million as it cut operating costs. Cash and cash equivalents were $5.435 million, with $0.250 million in restricted cash. Management states that cash on hand is not sufficient to fund planned operations beyond the next twelve months, and substantial doubt exists about the company’s ability to continue as a going concern.
Operating expenses fell sharply as R&D dropped to $0 in Q3 (from $2.239 million a year ago) and G&A was $1.577 million (from $2.142 million). A $3.161 million loss from the change in fair value of warrant liability was recognized before the warrants were amended and reclassified to equity. The company raised $3.3 million gross via a private placement of Series C Convertible Preferred Stock and accompanying warrants. Authorized common shares were increased to 500,000,000. Common shares outstanding were 5,901,091 as of September 30, 2025; 6,406,191 were outstanding as of November 6, 2025.
Disclosure controls and procedures were not effective due to an unresolved material weakness, with a remediation plan underway.